DD on Future growth and value creation of this stock - Big Money to be made here.
OWCP Looks to Bring Pharma-Grade Cannabis Therapeutics to Market!!!
OWCP is conducting clinical trials of cannabis-based treatments for multiple myeloma, psoriasis, fibromyalgia, post-traumatic stress disorder and migraines.
Multiple myeloma - orphan status designation
NEW YORK (GBI Research) - The global multiple myeloma treatment market value will expand from $7.3 billion in 2014 to $8.9 billion by 2021, representing a moderate Compound Annual Growth Rate (CAGR) of 4.6%, says business intelligence provider GBI Research. link http://www.fiercepharma.com/marketing/global-multiple-myeloma-treatment-market-value-to-approach-9-billion-by-2021-says-gbi-0 ----- A form of bone marrow cancer that accounts for 2% of all cancer deaths. In preliminary studies, the Company demonstrated that some combinations of THC and CBD led to the eradication of 100% of myeloma cells in 60% of the cultured cells within 24 to 48 hours of exposure to the cannabinoid formulation. These early stage in-vitro results may be limited, but they demonstrate significant potential within the market. Link http://www.baystreet.ca/viewarticle.aspx?id=437873
Psoriasis - marketing of a cannabinoid-based topical cream
The annual cost to society of anxiety disorders is estimated to be significantly over $42.3 billion, often due to misdiagnosis and under treatment. This includes psychiatric and non-psychiatric medical treatment costs, indirect workplace costs, mortality costs, and prescription drug costs. An estimated 8% of Americans - 24.4 million people - have PTSD at any given time. That is equal to the total population of Texas. link http://www.ptsdunited.org/ptsd-statistics-2/
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.